|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma Renin Activity Is an Independent Prognosticator in Patients With Myocardial Infarction.
|
31006732 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure was the number of secondary prevention medications (antiplatelets, β-blockers, statins, and renin-angiotensin-aldosterone system inhibitors) initiated after myocardial infarction.
|
31002274 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrated that progressive nephropathy in MI rats was associated with intrarenal activation of the renin-angiotensin-aldosterone system.
|
31228798 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.
|
30599150 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of the brain renin-angiotensin system by oral APA inhibitor is at least as effective as oral AT1R blocker to inhibit cardiac dysfunction after MI but without hypotension or renal dysfunction.
|
30531435 |
2019 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Baseline characteristics include female sex (25%), myocardial infarction as index ACS event (74%), coronary revascularization for index ACS (80%), treatment with dual anti-platelet therapy (87%) and renin-angiotensin system inhibitors (91%), median LDL cholesterol 65 mg per deciliter, and median HbA1c 7.3%.
|
31520897 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In post-MI mice, TSLP expression were up-regulated in cardiac tissue and serum, probably induced by renin-angiotensin system activation and AngII level up-regulation following MI.
|
31227217 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
All components of the cardiac renin-angiotensin system (RAS) are upregulated in myocardial infarction.
|
30840489 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study examined the effects of aliskiren (Ali) (direct renin inhibitor) on serum cardiac enzymes (LDH and CK-MB), electrocardiography (ECG) changes, myocardial oxidative stress markers (MDA, CAT, and GSH) and the expression of Bcl2, HO-1, and Nrf2 genes in isoproterenol (ISO)-induced myocardial infarction (MI).
|
29975120 |
2018 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Seven baseline variables were independently associated with ECR: prior coronary stent implantation (p < 0.0001), absence of prior myocardial infarction (p < 0.0001), higher low-density lipoprotein cholesterol (p < 0.0001), lower age (p < 0.0001), multivessel CAD (p = 0.003), diabetes mellitus (p = 0.005), and absence of treatment with renin-angiotensin system antagonists (p = 0.020).
|
29747917 |
2018 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study aimed to test whether angiotensin receptor blockers (ARBs) are cardioprotective after myocardial infarction (MI) by preventing augmented local renin-angiotensin-system (RAS)-induced oxidative stress injury and senescence, preserving resident stem cells, and restoring the insulin-like growth factor (IGF-1)/IGF-1 receptor (IGF-R) pathway.
|
30210678 |
2018 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, SNT has potential benefits of improving cardiac function by inhibiting the excessive activation of Renin-Angiotensin-Aldosterone system in heart failure after myocardial infarction in rats.
|
30050591 |
2018 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The low basal expression of cytosolic renin as well as its induction under ischemia-related conditions represents an efficient system regulated in accordance with its previously identified unfavorable effects under control situations but protective effects seen after myocardial infarction or glucose depletion.
|
28715805 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of the renin-angiotensin system (RAS) is beneficial in patient management after myocardial infarction (MI).
|
28204966 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure.
|
28166592 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual blood pressure (BP)-lowering and anti-inflammatory effect of renin-angiotensin-system (RAS) inhibitors may possess protective effect from MI in RA population.
|
29216228 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin system is involved in the pathogenesis of coronary artery disease and myocardial infarction (MI).
|
24167376 |
2013 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the renin-angiotensin system (RAS) plays a critical role in the pathophysiology of myocardial infarction (MI) and the development of heart failure.
|
24134599 |
2013 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen, one of the most important proteins in the renin-angiotensin system, plays a key role in the progress of coronary heart disease and myocardial infarction (MI).
|
23666149 |
2013 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarction.
|
21163865 |
2011 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that single nucleotide polymorphisms (SNPs) located in microRNA (miR) binding sites in genes of the renin angiotensin aldosterone system (RAAS) can influence blood pressure and risk of myocardial infarction.
|
21677697 |
2011 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of renin-angiotensin system and natriuretic peptide receptor A genes in patients of Greek origin with a history of myocardial infarction.
|
20529973 |
2010 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
|
18347611 |
2008 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors conducted a population-based, case-control study at Group Health (Seattle, Washington) between 1995 and 1999 to determine whether common haplotypes in the angiotensinogen gene (AGT), the renin gene, the angiotensin-converting enzyme gene, and the angiotensin II receptor type 1 and receptor type 2 genes were associated with the risk of myocardial infarction and stroke among pharmacologically treated hypertensive patients.
|
17522061 |
2007 |
|
Myocardial Infarction
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Logic regression for analysis of the association between genetic variation in the renin-angiotensin system and myocardial infarction or stroke.
|
17082497 |
2007 |